Hagop Kantarjian: Combination of venetoclax and hypomethylating agent provides high rates of durable remission and overall survival in both newly diagnosed and R/R IDH1/2-mutated Acute Myeloid Leukemia.

Quoting Hagop Kantarjian, Professor and Chair of the Department of Leukemia at MD Anderson Cancer Center, on X/Twitter:

“Combination of venetoclax and hypomethylating agent provides high rates of durable remission and overall survival in both newly diagnosed and R/R IDH1/2-mutated Acute Myeloid Leukemia.”

For details click here.
Source: Hagop Kantarjian/Twitter